Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) dropped 4.1% on Monday after Wedbush lowered their price target on the stock from $37.00 to $27.00. Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Monte Rosa Therapeutics Company Profile(Get Free Report)Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. See AlsoReceive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.